Русская версия English version   
Том 21   Выпуск 1   Год 2026
Список литературы

  1. Jee Y.M., Lee J.Y., Ryu T. Chronic inflammation and immune dysregulation in metabolic-dysfunction-associated steatotic liver disease progression: from steatosis to hepatocellular carcinoma. Biomedicines. 2025;13. Article No. 1260. doi: 10.3390/biomedicines13051260
  2. Nastasa R., Stanciu C., Stratina E., Zenovia S., Stafie R., Rotaru A., Sfarti C., Girleanu I., Minea H., Singeap A.M. et al. Screening of advanced fibrosis and metabolic dysfunction-associated steatotic liver disease using transient elastography in vulnerable population. Scientific Reports. 2025;15. Article No. 33028. doi: 10.1038/s41598-025-18733-0
  3. Nakamura T., Masuda A., Nakano D., Amano K., Sano T., Nakano M., Kawaguchi T. Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma. Cells. 2025;14. Article No. 428. doi: 10.3390/cells14060428
  4. Wynn T.A., Ramalingam T.R. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat. Med. 2012;18:1028–1040. doi: 10.1038/nm.2807
  5. Johnson P.J., Kalyuzhnyy A., Boswell E., Toyoda H. Progression of chronic liver disease to hepatocellular carcinoma: implications for surveillance and management. BJC Rep. 2024;2. Article No. 39. doi: 10.1038/s44276-024-00050-0
  6. Choi J.H. Histological and Molecular Evaluation of Liver Biopsies: A Practical and Updated Review. Int. J. Mol. Sci. 2025;26. Article No. 7729. doi: 10.3390/ijms26167729
  7. Chowdhury A.B., Mehta K.J. Liver biopsy for assessment of chronic liver diseases: a synopsis. Clin. Exp. Med. 2023;23:273–285. doi: 10.1007/s10238-022-00799-z
  8. Neuberger J., Cain O. The Need for Alternatives to Liver Biopsies: Non-Invasive Analytics and Diagnostics. Hepatic Med. Evid. Res. 2021;13:59–69. doi: 10.2147/HMER.S278076
  9. Cui M., Cheng C., Zhang L. High-throughput proteomics: a methodological mini-review. Lab Invest. 2022;102:1170–1181. doi: 10.1038/s41374-022-00830-7
  10. Vitorino R. Transforming Clinical Research: The Power of High-Throughput Omics Integration. Proteomes. 2024;12. Article No. 25. doi: 10.3390/proteomes12030025
  11. Kosti I., Jain N., Aran D., Butte A.J., Sirota M. Cross-tissue Analysis of Gene and Protein Expression in Normal and Cancer Tissues. Sci. Rep. 2016;6. Article No. 24799. doi: 10.1038/srep24799
  12. Wynn T.A., Ramalingam T.R. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat. Med. 2012;18:028–1040. doi: 10.1038/nm.2807
  13. Wang L., Huang Y., Chen J., Gao J., Chen S., Zhao M., Lin J., Zhou S., Shen Y., Cheng Y. Dynamic crosstalk between HSCs and liver microenvironment: multicellular interactions in the regulation of liver fibrosis. Front. Cell Dev. Biol. 2025;13. Article No. 1635763. doi: 10.3389/fcell.2025.1635763
  14. Zhang N., Yao H., Zhang Z., Li Z., Chen X., Zhao Y., Ju R., He J., Pan H., Liu X., et al. Ongoing involvers and promising therapeutic targets of hepatic fibrosis: The hepatic immune microenvironment. Front. Immunol. 2023;14. Article No. 1131588. doi: 10.3389/fimmu.2023.1131588
  15. Kishor A., Fritz S.E., Hogg J.R. Nonsense-mediated mRNA decay: the challenge of telling right from wrong in a complex transcriptome. Wiley Interdiscip Rev RNA. 2019;10. Article No. e1548. doi: 10.1002/wrna.1548
  16. Glisovic T., Bachorik J.L., Yong J., Dreyfuss G. RNA-binding proteins and post-transcriptional gene regulation. FEBS Lett. 2008;582:1977–1986. doi: 10.1016/j.febslet.2008.03.004
  17. Love M.I., Huber W., Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15. Article No. 550. doi: 10.1186/s13059-014-0550-8
  18. Chen E.Y., Tan C.M., Kou Y., Duan Q., Wang Z., Meirelles G.V., Clark N.R., Ma’ayan A. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics. 2013;14. Article No. 128. doi: 10.1186/1471-2105-14-128
  19. Ianevski A., Giri A.K., Aittokallio T. Fully-automated and ultra-fast cell-type identification using specific marker combinations from single-cell transcriptomic data. Nat. Commun. 2022;13. Article No. 1246. doi: 10.1038/s41467-022-28803-w
  20. Hao Y., Stuart T., Kowalski M.H., Choudhary S., Hoffman P., Hartman A., Srivastava A., Molla G., Madad S., Fernandez-Granda C. et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat. Biotechnol. 2024;42:293–304. doi: 10.1038/s41587-023-01767-y
  21. Suter P., Dazert E., Kuipers J., Ng C.K., Boldanova T., Hall M.N., Heim M.H. Multi-omics subtyping of hepatocellular carcinoma patients using a Bayesian network mixture model. PLoS Comput. Biol. 2022;18. Article No. e1009767. doi: 10.1371/journal.pcbi.1009767
  22. Williams M.J., Clouston A.D., Forbes S.J. Links Between Hepatic Fibrosis, Ductular Reaction, and Progenitor Cell Expansion. Gastroenterology. 2014;146:349–356. doi: 10.1053/j.gastro.2013.11.034
  23. Gribben C., Galanakis V., Calderwood A., Williams E.C., Chazarra-Gil R., Larraz M., Frau C., Puengel T., Guillot A., Rouhani F.J. et al. Acquisition of epithelial plasticity in human chronic liver disease. Nature. 2024;630:166–173. doi: 10.1038/s41586-024-07465-2
  24. Fayez S.S., Mishlish S.M., Saied H.M., Shaban S.A., Suleiman A.A., Hassan F., Al-Saffar A.Z., Al-Obaidi J.R. Role of Different Types of miRNAs in Some Cardiovascular Diseases and Therapy‐Based miRNA Strategies: A Mini Review. BioMed Research International. 2022;2022. Article No. 2738119. doi: 10.1155/2022/2738119
  25. Guicciardi M.E., Trussoni C.E., LaRusso N.F., Gores G.J. The Spectrum of Reactive Cholangiocytes in Primary Sclerosing Cholangitis. Hepatol. 2020;71:741–748. doi: 10.1002/hep.31067
  26. Yu F., Chen J., Wang X., Hou S., Li H., Yao Y., He Y., Chen K. Metabolic reprogramming of peritoneal mesothelial cells in peritoneal dialysis–associated fibrosis: therapeutic targets and strategies. Cell Commun. Signal. 2025;23. Article No. 114. doi: 10.1186/s12964-025-02113-2
  27. Li X., Sun X., Carmeliet P. Hallmarks of Endothelial Cell Metabolism in Health and Disease. Cell Metab. 2019;30:414–433. doi: 10.1016/j.cmet.2019.08.011
  28. Sato K., Marzioni M., Meng F., Francis H., Glaser S., Alpini G. Ductular Reaction in Liver Diseases: Pathological Mechanisms and Translational Significances. Hepatol. 2019;69:420–430. doi: 10.1002/hep.30150
  29. Sancho‐Bru P., Altamirano J., Rodrigo‐Torres D., Coll M, Millán C., Jose Lozano J., Miquel R., Arroyo V., Caballería J., Ginès P. et al. Liver progenitor cell markers correlate with liver damage and predict short-term mortality in patients with alcoholic hepatitis. Hepatology. 2012;55:1931–1941. doi: 10.1002/hep.25614
  30. Santos J.L., Kieling C.O., Meurer L., Vieira S., Ferreira C.T., Lorentz A., Silveira T.R. The extent of biliary proliferation in liver biopsies from patients with biliary atresia at portoenterostomy is associated with the postoperative prognosis. J. Pediatr. Surg. 2009;44:695–701. doi: 10.1016/j.jpedsurg.2008.09.013
  31. Ye F., Jing Y.Y., Guo S.W., Yu G.F., Fan Q.M., Qu F.F., Gao L., Yang Y., Wu D., Meng Y. et al. Proliferative ductular reactions correlate with hepatic progenitor cell and predict recurrence in HCC patients after curative resection. Cell & Biosci. 2014;4. Article No. 50. doi: 10.1186/2045-3701-4-50
  32. Zhao Y., Huang Z., Gao L., Ma H., Chang R. Osteopontin/SPP1: a potential mediator between immune cells and vascular calcification. Front. Immunol. 2024;15. Article No. 1395596. doi: 10.3389/fimmu.2024.1395596
  33. Yao C., Li Z., Su H., Sun K., Liu Q., Zhang Y., Zhu L., Jiang F., Fan Y., Shou S. et al. Integrin subunit beta 6 is a potential diagnostic marker for acute kidney injury in patients with diabetic kidney disease: a single cell sequencing data analysis. Ren. Fail. 2024;46. Article No. 2409348. doi: 10.1080/0886022X.2024.2409348
  34. Zheng Y., Xiong Z., Zhao L., Huang C., Yong Q., Fang D., Liu F., Li Y. The role of SPP1 in MASLD pathogenesis: Therapeutic insights into ursolic acid’s mechanisms of action: Correspondence to editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease.” Clin. Mol. Hepatol. 2024;30(4):1019–1022. doi: 10.3350/cmh.2024.0471
  35. Guillot A., Guerri L., Feng D., Kim S.J., Ait Ahmed Y., Paloczi J., He Y., Schuebel K., Dai S., Liu F., Pacher P. Bile acid–activated macrophages promote biliary epithelial cell proliferation through integrin αvβ6 upregulation following liver injury. J. Clin. Invest. 2021;131. Article No. e132305. doi: 10.1172/JCI132305
  36. Cichocka E., Górczyńska-Kosiorz S.B., Niemiec P., Trautsolt W., Gumprecht J. The Impact of Selected COL1A1 and COL1A2 Gene Polymorphisms on Bone Mineral Density and the Risk of Metabolic Diseases in Postmenopausal Women. Int. J. Mol. Sci. 2025;26(11). Article No. 4981. doi: 10.3390/ijms26114981
  37. Gao R., Wang J., He X., Wang T., Zhou L., Ren Z., Yang J., Xiang X., Wen S., Yu Z. et al. Comprehensive analysis of endoplasmic reticulum-related and secretome gene expression profiles in the progression of non-alcoholic fatty liver disease. Front. Endocrinol. 2022;13. Article No. 967016. doi: 10.3389/fendo.2022.967016
  38. Almanaa T.N., Alamri A., Abdel-Maksoud M.A., Saleh I.A., Zomot N., Al-Hawadi J.S., Al-Qahtani W.H., Hameed Y. COL1A1, ITGB1, THY1, and PDGFRA: key immune-related genes in uterine corpus endometrial carcinoma with prognostic and therapeutic implications. Hereditas. 2025;162. Article No. 159. doi: 10.1186/s41065-025-00448-x
Содержание Оригинальная статья
Hawraa M. Alaa Alden, Haneen Rafea Ali, Afrah Jabbar Lazim, Ahmed AbdulJabbar Suleiman Integrative Bioinformatics Analysis of Liver Transcriptomics and Serum Fibroblast Growth Factor 21 Protein Levels in Monitoring Progressive Fibrotic Liver Disease. Маthematical biology and bioinformatics. 2026;21(1):175-186. doi: 10.17537/2026.21.175
(опубликована на англ. яз.)

Аннотация (англ.)
Аннотация (рус.)
Полный текст (англ., pdf)
Список литературы

 

  Copyright ИМПБ РАН © 2005-2026